This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

46/100

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Health systems and care delivery

Topic: Amyloid, tau and blood-test diagnosis

In total, 147 participants across 21 US sites were invited to participate and 111 provided informed consent. Of those, 61 patients had linkable data (ie, Medicare beneficiary identifier), Medicare Parts A/B enrollment, and no health maintenance organization (HMO) enrollment in the year before trial entry. Of the 61 participants whose data were analyzed in this study, 30 had MCI due to AD and 31 had mild AD dementia. Participants in the MCI due to AD group had more healthcare resource utilization on average in the baseline period than those in the mild AD dementia group (29.9 [SD, 20.9] vs 24.5 claims [SD, 12.3]). In an ad hoc analysis, a relatively high concordance (85.3%) was seen between the rates of clinically confirmed AD diagnosis and evidence of AD diagnosis in claims data. This linkage process may serve as a proof of concept for researchers interested in linking clinical trial and real-world claims data. The lessons learned from AD-LINE and innovation of data linkage approaches may encourage key stakeholders to link data in the future.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Fillit, H. M., Assunção, S. S., Majda, T., Ng, C., To, T., Abbass, I. M., et al. (2024). Alzheimer's Disease Linkage to Real-World Evidence (AD-LINE) Study: Linking Claims Data to Phase 3 GRADUATE Study of Gantenerumab. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.14283/jpad.2024.115

Vancouver

Fillit HM, Assunção SS, Majda T, Ng C, To T, Abbass IM, et al. Alzheimer's Disease Linkage to Real-World Evidence (AD-LINE) Study: Linking Claims Data to Phase 3 GRADUATE Study of Gantenerumab. The Journal of Prevention of Alzheimer s Disease. 2024. doi:10.14283/jpad.2024.115. PMID: 39350370.

BibTeX

@article{fillit2024-39350370,
  author  = {Fillit, Howard M and Assunção, Sheila Seleri and Majda, Thomas and Ng, C.D. and To, T. and Abbass, Ibrahim M. and Raimundo, Karina and Wallick, CJ and others},
  title   = {{Alzheimer's Disease Linkage to Real-World Evidence (AD-LINE) Study: Linking Claims Data to Phase 3 GRADUATE Study of Gantenerumab}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year    = {2024},
  doi     = {10.14283/jpad.2024.115},
  pmid    = {39350370},
  url     = {https://doi.org/10.14283/jpad.2024.115}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

In total, 147 participants across 21 US sites were invited to participate and 111 provided informed consent.
Of those, 61 patients had linkable data (ie, Medicare beneficiary identifier), Medicare Parts A/B enrollment, and no health maintenance organization (HMO) enrollment in the year before trial entry.
Of the 61 participants whose data were analyzed in this study, 30 had MCI due to AD and 31 had mild AD dementia.
Participants in the MCI due to AD group had more healthcare resource utilization on average in the baseline period than those in the mild AD dementia group (29.9 [SD, 20.9] vs 24.5 claims [SD, 12.3]).
In an ad hoc analysis, a relatively high concordance (85.3%) was seen between the rates of clinically confirmed AD diagnosis and evidence of AD diagnosis in claims data.

Why it matters

This study linked claims data to a phase 3 trial of gantenerumab and found relatively high agreement between clinically confirmed Alzheimer's diagnoses and claims data. It is a data-linkage methods study and reports no results on whether gantenerumab treats, cures, or prevents Alzheimer's disease.

Study details

Study designcohort study
Participants147
Effect size85.3%
Evidence strengthModerate

How this study scored 46/100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 45 of the 97 points we could judge it on, which is 46 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease)
Journal's citation record	0 / 4	The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	2 / 4	147 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 2 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.5 citations a year over 4 year(s) since 2024
Impact for its field and year	1 / 6	Cited 0.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Oleg V Tcheremissine: h-index 19 (OpenAlex, whole career)
Institution's track record	— / 3	No institution listed in OpenAlex — left out of this score
Multicenter collaboration	0 / 3	OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 39350370)
Free to read	2 / 2	Free to read
Points	45 / 97	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 97 points we could judge it on is 46 out of 100.
Total	46 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Health systems and care delivery

Also in Health systems and care delivery

172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.

Similar studies

More on Health systems and care delivery

Where this led: Gantenerumab on the treatments page — its current status, approval date, side-effect rate and list price, kept up to date.

See all studies in Health systems and care delivery →